FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma

Share:

Listens: 0

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Science

FDA medical oncologists discuss the December 20, 2017, approval of nivolumab for the adjuvant treatment of patients with melanoma.